# Povidone-iodine to Stop Access-related Infections and Transmission of Staphylococcus aureus (PAINTS)

> **NIH AHRQ R01** · UNIVERSITY OF IOWA · 2022 · $223,172

## Abstract

Abstract
Background: The long-term objective of the “Povidone-iodine to stop Access related INfections and
Transmission of Staphylococcus aureus (PAINTS)” proposal is to decrease rates of healthcare-
associated infections that occur outside of the hospital (i.e., community-onset infections). Recent data
from the Centers for Disease Control and Prevention (CDC) demonstrated that 83% of methicillin-
resistant Staphylococcus aureus (MRSA) bloodstream infections are community-onset. Hemodialysis
patients are at high-risk for community-onset bloodstream infections, particularly S. aureus access-
related bloodstream infections (ARBSI). These infections cause increased morbidity and mortality.
Nasal povidone-iodine decolonization is a novel intervention that can potentially prevent S. aureus
ARBSI in this patient population. Specific Aims: Aim 1: Assess whether nasal povidone-iodine
decolonization reduces infections among hemodialysis patients using a multicenter, stepped-wedge
cluster randomized trial. Primary outcome: S. aureus ARBSI. Secondary outcomes: Other S. aureus
dialysis-associated infections as defined by the CDC National Healthcare Safety Network, ARBSI
caused by pathogens other than S. aureus, all dialysis-associated infections caused by all pathogens,
and S. aureus colonization and transmission. Aim 2: Evaluate patient satisfaction with nasal povidone-
iodine decolonization, assess its role in patient activation, and assess barriers and facilitators to
implementation using patient surveys. Aim 3: Examine healthcare worker satisfaction with
implementation of nasal povidone-iodine decolonization and assess barriers and facilitators to the
process via qualitative interviews and site visits. Research Design: We aim to perform a randomized
stepped wedge study among 16 hemodialysis units affiliated with 5 geographically diverse healthcare
centers to evaluate whether nasal povidone-iodine will reduce rates of S. aureus ARBSI among
hemodialysis patients. These hemodialysis units represent both rural and inner-city patients who
receive chronic care (AHRQ priority populations). We will survey all patients and qualitatively interview
healthcare workers to assess the acceptability and feasibility of this intervention, as well as barriers and
facilitators to implementation. We will test patients' noses for S. aureus colonization to determine
whether nasal povidone-iodine decreases S. aureus colonization and S. aureus transmission. The sites
that will participate in this study (University of Iowa, University of Illinois, University of Pennsylvania,
Washington University, Emory Healthcare) have a good history of collaboration. Relevance: This study
will help AHRQ address its goal to “build the evidence for fighting antibiotic resistance in the ambulatory
setting,” and help meet the National Action Plan to Prevent Healthcare-Associated Infections
recommendation that hemodialysis centers aim to improve ARBSI rates.

## Key facts

- **NIH application ID:** 10329904
- **Project number:** 5R01HS026724-04
- **Recipient organization:** UNIVERSITY OF IOWA
- **Principal Investigator:** Marin Leigh Schweizer
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** AHRQ
- **Fiscal year:** 2022
- **Award amount:** $223,172
- **Award type:** 5
- **Project period:** 2019-04-01 → 2022-05-01

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10329904

## Citation

> US National Institutes of Health, RePORTER application 10329904, Povidone-iodine to Stop Access-related Infections and Transmission of Staphylococcus aureus (PAINTS) (5R01HS026724-04). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10329904. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*